Enorama Pharma (Sweden) Analysis
| ERMA Stock | SEK 3.76 0.13 3.34% |
Enorama Pharma AB is overvalued with Real Value of 3.53 and Hype Value of 3.76. The main objective of Enorama Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Enorama Pharma AB is worth, separate from its market price. There are two main types of Enorama Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Enorama Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Enorama Pharma's stock to identify patterns and trends that may indicate its future price movements.
The Enorama Pharma stock is traded in Sweden on Stockholm Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Sweden. Enorama Pharma is usually not traded on NationalDay, International Workers ' Day, St . John 's Day, All Saints ' Day, Christmas Eve, Christmas Day, Boxing Day, New Year 's Day, Epiphany, Good Friday, Easter Sunday, Easter Monday. Enorama Stock trading window is adjusted to Europe/Stockholm timezone.
Enorama |
Enorama Stock Analysis Notes
About 78.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.92. Enorama Pharma AB had not issued any dividends in recent years. The entity had 1726:1687 split on the 29th of October 2018. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden. To learn more about Enorama Pharma AB call Mats Rnngard at 46 7 08 72 82 50 or check out https://www.enorama.se.Enorama Pharma AB Investment Alerts
| Enorama Pharma AB generated a negative expected return over the last 90 days | |
| Enorama Pharma AB has high historical volatility and very poor performance | |
| Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M. | |
| Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 78.0% of Enorama Pharma shares are held by company insiders |
Enorama Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 89.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enorama Pharma's market, we take the total number of its shares issued and multiply it by Enorama Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 27th of November, Enorama Pharma shows the Variance of 30.33, mean deviation of 4.16, and Standard Deviation of 5.51. Enorama Pharma AB technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enorama Pharma AB Price Movement Analysis
The output start index for this execution was three with a total number of output elements of fifty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Enorama Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Enorama Pharma AB. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Enorama Pharma Outstanding Bonds
Enorama Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enorama Pharma AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enorama bonds can be classified according to their maturity, which is the date when Enorama Pharma AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Enorama Pharma Predictive Daily Indicators
Enorama Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enorama Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Enorama Pharma Forecast Models
Enorama Pharma's time-series forecasting models are one of many Enorama Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Enorama Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Enorama Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Enorama Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Enorama shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Enorama Pharma. By using and applying Enorama Stock analysis, traders can create a robust methodology for identifying Enorama entry and exit points for their positions.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Enorama Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.